{"id":1017692,"date":"2026-11-05T11:20:35","date_gmt":"2026-11-05T16:20:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"modified":"2026-11-05T11:20:35","modified_gmt":"2026-11-05T16:20:35","slug":"retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","title":{"rendered":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FALLS CHURCH, Va., Nov.  05, 2026  (GLOBE NEWSWIRE) &#8212; Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (\u201cRetension\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9\u201311, 2026, in Boston, Massachusetts.<\/p>\n<p>\n        <strong>Event: <\/strong>Guggenheim 3rd Annual Healthcare Innovation Conference<br \/><strong>Format: <\/strong>Fireside chat<br \/><strong>Date: <\/strong>Tuesday, November 10, 2026<br \/><strong>Time: <\/strong>7:30 a.m. ET<\/p>\n<p>A live webcast of this fireside chat can also be accessed on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=266SRvE5GfIQOUsy0AbEewKrCkHerqYc-UB0_D1j8SdPKwEfQqiHfD-fDX4GbuSHVBFPpXfhDtqBQaPnPyvF3W-i6T_SDpu7-4PUPWssQl0n_GZF1aBxUApnDGI1qDn_oFPuB_Lg1nSsd23OB5qXOA==\" rel=\"nofollow\" target=\"_blank\">News &amp; Events<\/a>\u201d page in the Investor Relations section of the Retension Pharmaceuticals website.<\/p>\n<p>\n        <strong>About Retension Pharmaceuticals<\/strong>\n      <\/p>\n<p>Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company\u2019s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.<\/p>\n<p>\n        <strong>About RTN-001<\/strong>\n      <\/p>\n<p>Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects. In two Phase 2 pilot trials, RTN-001 has achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure and diastolic blood pressure in patients with hypertension. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Press and Investor Contact<\/strong><br \/>\n        <br \/>Alex Schwartz<br \/>Chief Financial Officer<br \/>investors@retensionpharmaceuticals.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E4MTJiZTItZjU1Mi00NWFhLThiODktMmYxMDY2MmQ1NTdjLTEzMzYzOTQtMjAyNi0xMS0wNS1lbg==\/tiny\/Retension-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (\u201cRetension\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9\u201311, 2026, in Boston, Massachusetts. Event: Guggenheim 3rd Annual Healthcare Innovation ConferenceFormat: Fireside chatDate: Tuesday, November 10, 2026Time: 7:30 a.m. ET A live webcast of this fireside chat can also be accessed on the \u201cNews &amp; Events\u201d page in the Investor Relations section of the Retension Pharmaceuticals website. About Retension Pharmaceuticals Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017692","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (\u201cRetension\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9\u201311, 2026, in Boston, Massachusetts. Event: Guggenheim 3rd Annual Healthcare Innovation ConferenceFormat: Fireside chatDate: Tuesday, November 10, 2026Time: 7:30 a.m. ET A live webcast of this fireside chat can also be accessed on the \u201cNews &amp; Events\u201d page in the Investor Relations section of the Retension Pharmaceuticals website. About Retension Pharmaceuticals Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the &hellip; Continue reading &quot;Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T16:20:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\",\"datePublished\":\"2026-11-05T16:20:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\",\"datePublished\":\"2026-11-05T16:20:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (\u201cRetension\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9\u201311, 2026, in Boston, Massachusetts. Event: Guggenheim 3rd Annual Healthcare Innovation ConferenceFormat: Fireside chatDate: Tuesday, November 10, 2026Time: 7:30 a.m. ET A live webcast of this fireside chat can also be accessed on the \u201cNews &amp; Events\u201d page in the Investor Relations section of the Retension Pharmaceuticals website. About Retension Pharmaceuticals Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the &hellip; Continue reading \"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T16:20:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference","datePublished":"2026-11-05T16:20:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"wordCount":257,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","name":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=","datePublished":"2026-11-05T16:20:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDY5NSM3OTQ2MTM1IzIzMjQ4NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retension-pharmaceuticals-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017692"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}